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Introduction: According to studies, statins possess analgesics and anti-inflammatory 
properties. In the present study, we examined the antinociceptive, anti-inflammatory and 
antioxidative effects of rosuvastatin in an experimental model of Chronic Constriction 
Injury (CCI).
Methods: Our study was conducted on four groups; sham, CCI (the control group), 
CCI+rosuvastatin (i.p. 5 mg/kg), and CCI+rosuvastatin (i.p. 10 mg/kg). We performed heat 
hyperalgesia, cold and mechanical allodynia tests on the 3rd, 7th, 14th, and 21st after inducing 
CCI. Blood samples were collected to measure the serum levels of Tumor Necrosis Factor 
(TNF)-α, and Interleukin (IL)-6. Rats’ spinal cords were also examined to measure tissue 
concentration of Malondialdehyde (MDA), Superoxide Dismutase (SOD), and Glutathione 
Peroxidase (GPx) enzymes. 
Results: Our findings showed that CCI resulted in significant increase in heat hyperalgesia, 
cold and mechanical allodynia on the 7th, 14th and 21st day. Rosuvastatin use attenuated 
the CCI-induced hyperalgesia and allodynia. Rosuvastatin use also resulted in reduction of 
TNF-α, IL-6, and MDA levels. However, rosuvastatin therapy increased the concentration 
of SOD and GPx in the CCI+Ros (5 mg/kg) and the CCI+Ros (10 mg/kg) groups compared 
to the CCI group. 
Conclusion: Rosuvastatin attenuated the CCI-induced neuropathic pain and inflammation. 
Thus, antinociceptive effects of rosuvastatin might be channeled through inhibition of 
inflammatory biomarkers and antioxidant properties.
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Highlights 
• Rosuvastatin administration significantly increases anti-inflammatory activity.
• Rosuvastatin administration significantly increases antioxidant activity.
• Rosuvastatin administration significantly increases antinociceptive activity.
Plain Language Summary 
Neuropathic pain includes the unpleasant sensations of burning and tingling, increased sensitivity towards the hyperalgesia 
and pain due to allodynia. Both hyperalgesia and allodynia coexist in the hyperinflammatory and neuropathic pains. Rosuvas-
tatin, the cholesterol-lowering drug, activates the inhibitory reductase enzyme of 3-Hydroxy-3-Methylglutaryl-Coenzyme 
(HMG-CoA), which is widely used in the treatment of dyslipidemia and hypercalcemia. Recent studies suggest that rosuvastatin 
possesses dose-dependent antioxidant, anti-inflammatory, and analgesic activities. Several studies have shown that anti-inflam-
matory property of rosuvastatin through the leukocyte adhesion inhibition reduces the production of inflammatory mediators 
and their antioxidant effects. 
The purpose of the current study was to assess the analgesic, anti-inflammatory and antioxidative effects of rosuvastatin in 
animals with neuropathic pain due to chronic constriction injury. Animals were randomly divided into four experimental groups 
(n=10 in each group): 1. Sham-operated; 2. CCI vehicle-treated (CCI); 3. CCI+Rosuvastatin (Ros) (5 mg/kg); and 4. CCI+Ros 
(10 mg/kg). The study results showed that the rosuvastatin was effective in reducing neuropathic pains, where the inflammatory 
factors play a key role. Rosuvastatin is an anticholesterol drug, which reduces the level of the inflammatory factors with its ben-
eficial effects on neuropathic pain. Briefly, rosuvastatin can reduce the production of the inflammatory mediators and neuronal 
damage, thus improves the neuropathic pain in CCI model.
N
1. Introduction
europathic pain (central or peripheral) is 
a complex chronic condition which re-
sults from nerve damage and dysfunction. 
Neuropathic pain symptoms include an 
unpleasant sensation of burning or tin-
gling, increased sensitivity to the noxious 
stimuli (hyperalgesia) and pain due to innocuous stimuli 
(allodynia) (Dworkin et al., 2003). Central and peripheral 
mechanisms of Neuropathic Pain (NP) consist of changes 
in ion channel expression and nerve neurotransmitter re-
lease (Zhuo, 2007). Several factors are associated with 
neuropathic syndromes, including chronic disorders like 
diabetes and stroke, injury (spinal cord injury, multiple 
sclerosis), and infection (HIV-related neuropathies). 
When tissues and nerves get injured, pain recep-
tors are activated due to inflammatory stimulation (De 
Jongh et al., 2003). Inflammation is a potent modifier of 
responses to both noxious stimuli (hyperalgesia) and in-
nocuous stimuli (allodynia) (Zanjani et al., 2006). Several 
experimental studies have shown that Reactive Oxygen 
Species (ROS) contribute to hyperalgesia and allodynia 
(Kim et al., 2004; Trevisan et al., 2016). Proinflammatory 
cytokines including Interleukin (IL)-6 and Tumor Necrosis 
Factor (TNF)-α play significant roles in neuronal reaction 
and inflammation. Both might also induce nerve injury. 
Statins known as 3-Hydroxy-3-Methylglutaryl-Co-
enzyme (HMG-CoA) reductase inhibitors are widely 
used as lipid-lowering medications to treat dyslipidemia 
(Murrow et al., 2012). HMG-CoA reductase is an en-
zyme of the mevalonate pathway that produces isopren-
oids (with the exception of cholesterol synthesis). Studies 
have suggested that mevalonic acid has a significant role 
in intracellular events, e.g. apoptosis, inflammation, leu-
kocyte migration, adhesion, and clotting (Coward, Ma-
rei, Yang, Vasa-Nicotera, & Chow, 2006). It has been 
shown that statins medications have anti-inflammatory, 
anti-oxidative, and neuronal protection effects in patho-
logical conditions (Gholami et al., 2008; Koh, Sakuma, 
& Quon, 2011; Mohammadi, Amini, Jahanbakhsh, & 
Shekarforoush, 2013). Rosuvastatin, compared to the 
other statins, is a relatively potent HMG-CoA reductase 
inhibitor with a high degree of selectivity for liver cells 
(McTaggart, 2003). 
The novelty of this research is to find out the analgesic, 
anti-inflammatory, and antioxidative effects of rosuvas-
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tatin in animals with neuropathic pain due to Chronic 
Constriction Injury (CCI).
2. Methods
2.1. Animals and housing conditions
Forty male adult Sprague–Dawley rats, weighing 
200-250 g, were purchased from Razi Herbal Medicine 
Research Center (Khorramabad, Iran). Animals were 
housed at a temperature of 23±2°C, humidity of ap-
proximately 50%, and 12:12 h light/dark cycle with free 
access to water and standard food. 
2.2. Study design
Animals were randomly divided into four experimen-
tal groups (n=10 in each group): 1. Sham-operated (Sh); 
2. CCI vehicle-treated (CCI); 3. CCI+Rosuvastatin 
(Ros) (5 mg/kg) (Ferreira et al., 2014); and 4. CCI+Ros 
(10 mg/kg) (Mayanagi, Katakam, Gáspár, Domoki, & 
Busija, 2008). Rosuvastatin was injected once per day 
before the operation and continued daily until the 21st 
day post-ligation. 
2.3. Drug preparation
Rosuvastatin (Sigma-Aldrich, St. Louis, MO, USA) 
was suspended in distilled water as vehicle. Pentobar-
bital sodium (Sigma-Aldrich, St. Louis, MO, USA) was 
used for anesthesia. All drugs were prepared freshly and 
injected by the intraperitoneal (i.p.) route.
2.4. Operation
We used chronic constriction injury model to induce 
neuropathic pain in animals. The operation was per-
formed under pentobarbital sodium (60 mg/kg) anesthe-
sia. After anesthesia, skin and muscle were separated and 
left sciatic nerve was exposed. Next, we carefully tied 4 
chromic gut ligatures loosely around sciatic nerves. The 
space between two adjacent ligatures was 1 mm. The 
wound was irrigated with sterile normal saline (0.9%) 
and sutured in two layers with non-absorbable sutures 
(fascial plane), and finally surgical skin staples. In the 
sham-operated group, the same surgical procedure (ex-
cept the ligation) was performed (Bennett & Xie, 1988).
2.5. Thermal stimulation tests
In order to assess rosuvastatin effect on neuropathic 
pain, behavioral tests were recorded on days 3, 7, 14, 
and 21 after inducing CCI. The experiment started with 
mechanical test and terminated with cold allodynia. 
Sixty minutes were considered as the interval time of 
the two tests. 
2.5.1. Heat hyperalgesia stimulation (Hot Plate Test)
Heat hyperalgesia was measured using a hot plate test 
animal. Each animal was placed on the hot plate (tem-
perature of 52.5±1.0°C). Afterward, paw withdrawal 
latency, with respect to licking of the hind paw and 
jumping, was recorded in seconds. The cut-off time of 
10 seconds was maintained (Li et al., 2015).
2.5.2. Cold allodynia (Acetone Test)
In this test, the animal’s hind paws were located over 
a wire mesh and acetone was sprayed onto its surface 
without touching the paw (100 μL). Then, the animal’s 
response to acetone was noted in 20 s and scored ac-
cording to 4-point Kukkar and Singh scale. For ob-
taining a single score for a cumulative period of 60 s, 
individual scores for each 20 s intervals were added 
over. The score range was defined from 0 to 9 (Kukkar, 
Singh, & Jaggi, 2013). 
2.5.3. Mechanical allodynia (Von Frey Test)
Mechanical allodynia was determined by using von 
Frey filaments. When rats were adapted to the cages, 
the von Frey filament was applied by increasing the 
strength gently (2-60 g) of central region in plantar sur-
face of hind paws until the animal lifts the paw away 
(Banafshe et al., 2012).
2.6. Elisa assay
In order to evaluate the serum levels of Tumor Ne-
crosis Factor alpha (TNF-α) and Interleukin 6 (IL-6), 
on the day 21 after the operation, the blood sample 
was collected from the jugular vein. TNF-α and IL-6 
levels were measured by solid phase sandwich ELISA 
kit specified for TNF-α protein and IL-6 (Cusabio, Bio-
tech, Wuhan, Hubei, China). The analysis of TNF-α 
and IL-6 protein expression were calibrated accord-
ing to the manufacturer’s instructions. Superoxide 
Dismutase (SOD), Glutathione Peroxidase (GPx) and 
Malondialdehyde (MDA) were estimated in fresh spi-
nal cord after spinal dislocation. For this purpose, the 
rats’ spinal cords were isolated immediately on the day 
21 after behavioral measurements. 
Then, the homogenate tissue was prepared with 0.9% 
saline using glass homogenate and centrifuged at 2500 
rpm for 10 min. Homogenate supernatant (10%, w/v) 
was used for these tests. Superoxide Dismutase (SOD) 
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and GPx and Malondialdehyde (MDA) levels were 
estimated by using specific quantitative kits (Moham-
madi et al., 2013).
2.7. Histological study
Sciatic nerves were separated on day 21 after operation. 
Histological studies were accomplished according to the 
protocol. Samples were then cut into 5- µM sections 
and stained with H&E. A pathologist who was blinded 
to the study analyzed the slides using a well-established 
scales for perineural measurement (Brummett, Padda, 
Amodeo, Welch, & Lydic, 2009).
2.8. Statistical analysis
Behavioral data were analyzed by 2-way ANOVA 
followed by a post hoc Tukey test. Also inflammatory 
cytokines, oxidative stress and pathological dates were 
analyzed by 1-way ANOVA followed by a post hoc Dun-
nett test. In all cases P≤0.05 was considered statistically 
significant. All data were expressed as mean±SED (Us-
ing GraphPad Prism Version 5.0).
3. Results
3.1. Rosuvastatin effect on heat hyperalgesia (Hot 
plate test)
Figure 1 shows rosuvastatin effect on hyperalgesia heat 
stimulation in the treatment groups compared with the 
CCI group. The CCI model significantly showed in-
crease in withdrawal latency time to hyperalgesia heat 
stimulation compared to the sham group on the 7th, 14th, 
and 21st days of study (P<0.01, P<0.01 and P<0.001, re-
spectively). In addition, there were significant differenc-
es between the CCI+Ros (10 mg/kg) and the CCI group 
on day 7 (P<0.05) regarding the heat stimulation score. 
Moreover, there was a significant difference between 
the sham and the CCI+Ros (10 mg/kg) group on the 21st 
day of study (P<0.001). Also, a significant difference 
was observed between the CCI+Ros (5 mg/kg) and the 
CCI+Ros (10 mg/kg) group on day 21 (P<0.05). There 
was no significant difference between the CCI and the 
CCI+Ros (5 mg/kg) in all days.
3.2. Rosuvastatin effect on cold allodynia (ac-
etone test)
Figure 2 shows increasing response to the stimulation 
caused by acetone spray on the rats’ feet sole subject to 
the imperfect ligation of the sciatic nerve that indicates the 
induction of neuropathic pain among the CCI rats. These 
differences were between all groups compared to the CCI 
group on the 3rd, 7th, 14th, and 21st days. In addition, there 
was significant differences in the CCI+Ros (5 mg/kg) com-
pared to the CCI+Ros (10 mg/kg) group on the 7th, 14th and 
21st days (P<0.05, P<0.001 and P<0.001, respectively).
3.3. Rosuvastatin effect on mechanical allodynia
Figure 3 shows rosuvastatin effect on mechanical allo-
dynia stimulation in the treatment groups compared with 
the sham and the CCI groups. The CCI model resulted 
Figure 1. Effect of rosuvastatin treatment on hyperalgesia 
heat stimulation score in study groups 
Significant difference in heat stimulation score activity in 
the CCI+Ros (5 mg/kg) and CCI+Ros (10 mg/kg) groups 
compared to the sham group. Significant difference in heat 
stimulation score in the CCI+Ros (10 mg/kg) group com-
pared to the CCI group.
*P<0.05 vs CCI; **P<0.01 vs CCI; ***P<0.001 vs CCI; #P<0.05 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg)
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Figure 2. Effect of rosuvastatin treatment on cold allodynia 
stimulation test in study groups 
Significant difference was seen in heat stimulation score in 
the CCI+Ros (5 mg/kg) and CCI+Ros (10 mg/kg) groups 
compared to the CCI group.
*P<0.05 vs CCI; **P<0.01 vs CCI; ***P<0.001 vs CCI; #P<0.05 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg); ##P<0.01 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg); ###P<0.001 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg)
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in significant increase in paw withdrawal latency to me-
chanical allodynia stimulation compared to the sham 
group on the 3rd, 7th, 14th and 21st days of study (P<0.05, 
P<0.01, P<0.001, and P<0.001, respectively). In addi-
tion, there were significant differences in paw withdraw-
al latency in the CCI+Ros (5 mg/kg) (P<0.05, P<0.01 
and P<0.001, respectively) and the CCI+Ros (10 mg/kg) 
(P<0.05, P<0.001, and P<0.001, respectively) compared 
to the CCI group on the 7th, 14th and 21st days. No signifi-
cant differences were observed between the CCI+Ros (5 
mg/kg) and the CCI+Ros (10 mg/kg) in all days.
3.4. Rosuvastatin effect on tumor necrosis factor-
alpha and interlukin-6 protein analysis 
As shown in Figure 4, TNF-α and IL-6 concentra-
tion increased significantly compared to those in the 
sham group (P<0.001). Rosuvastatin use reduced the 
increment ratio of TNF-α and IL-6 concentration in 
the CCI+Ros (5 mg/kg) and the CCI+Ros (10 mg/kg) 
groups compared to the CCI group. 
3.5. Rosuvastatin effect on malondialdehyde, super-
oxide dismutase, and glutathione peroxidase 
Figure 5 shows a significant increase in MDA activity 
in the CCI group compared to the sham group (P<0.001). 
The CCI+Ros (5 mg/kg) and the CCI+Ros (10 mg/kg) 
groups showed significant decrease in MDA activity as 
compared to the CCI group (P<0.001). Also, the result 
showed a significant decrease in SOD and GPx activities 
in the CCI group compared to the sham group (P<0.001). 
The CCI+Ros (10 mg/kg) showed a significant increase 
in SOD activity as compared to the CCI group, but not 
the CCI+Ros (5 mg/kg) group. As shown in Figure 5, 
both Ros (5 mg/kg and 10 mg/kg) administration signifi-
cantly increased the GPx activity as compared to the CCI 
group (P<0.01 and P<0.001, respectively). 
3.6. Rosuvastatin effect on histological study
Our result showed little signs of inflammation in the 
sciatic nerve in the sham group. Moreover, histologi-
cal findings showed an extensive perineural inflamma-
tion in the sciatic nerve in the CCI. Also, the histologi-
cal study showed a low inflammation ratio around the 
sciatic nerve in the CCI+Ros (10 mg/kg) group. In this 
Figure 3. Effect of rosuvastatin treatment on mechanical al-
lodynia stimulation test in study groups 
Significant difference was seen in heat stimulation score in 
the CCI+Ros (5 mg/kg) and CCI+Ros (10 mg/kg) groups 
compared to the CCI group.
*P<0.05 vs CCI. **P<0.01 vs CCI. ***P<0.001 vs CCI. #P<0.05 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg), ##P<0.01 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg), ###P<0.001 
CCI+Ros (5 mg/kg) vs CCI+Ros (10 mg/kg).
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Figure 4. Effect of rosuvastatin treatment on TNF-α and IL_6 concentration in study groups
Significant difference was observed in TNF-α and IL-6 activity in the sham, CCI+Ros (5 mg/kg) and CCI+Ros (10 mg/kg) 
groups compared to the CCI group.
*P<0.5; ** P<0.01; and ***P<0.001 compared to the CCI group.
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study, nerve injury was not detected in sciatic nerve of all 
groups (Figure 6).
4. Discussion
CCI model is one of the most common models to in-
duce neuropathic pain (Jaggi, Jain, & Singh, 2011). In 
our study, the CCI model significantly caused allodynia 
and hyperalgesia on the 21st day after operation. We 
clearly demonstrated that rosuvastatin use (5 and 10 mg 
in a duration of 21 days) significantly improved behav-
ioral changes of the induced CCI model, including heat 
hyperalgesia, cold allodynia and mechanical allodynia in 
the rat model of CCI-induced neuropathic nociception. 
Rosuvastatin treatment suppressed neuropathic-induced 
overexpression of inflammatory serum cytokines such as 
TNF-α, IL-6. Also, rosuvastatin attenuated the levels of 
oxidative markers like MDA, SOD and GPx in the spinal 
cord. The best result belonged to 10 mg/kg of rosuvas-
tatin administration.
Figure 6. Histological and morphological studies in sciatic nerve at 21 days after CCI induction 
In an untreated CCI rats (B), the sciatic nerve has diffuse areas of moderate to marked edema/cellular infiltrate. In the Ros-
treated (10 mg/kg) CCI rats (D), the finding is small focal areas of mild edema and/or cellular infiltrate. A: Sham; B: CCI; C: 
CCI+rosuvastatin (5 mg/kg); D: CCI+rosuvastatin (10 mg/kg) 
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Figure 5. Effect of Rosuvastatin treatment on MDA, SOD and GPx activity in study groups
Significant differences were seen in MDA, SOD and GPx activity in the sham, CCI+Ros (5 mg/kg) and CCI+Ros (10 mg/kg) 
groups compared to the CCI group.
**P<0.01; and ***P<0.001 compared to the CCI group.
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Rosuvastatin is categorized in the statin family, which 
can reduce the blood cholesterol levels through HMG-
CoA reductase pathway inhibition. Statins have inde-
pendent cholesterol lowering effect, antioxidant effect 
(Uekawa et al., 2014), anti-inflammatory effect (de Vries 
et al., 2014), antibacterial effect (Lopez-Cortes et al., 
2013), and most importantly neuroprotective effect (Wu 
et al., 2008). Many studies have shown various statins 
effects e.g. decreasing levels of inflammatory cytokines 
(Chu et al., 2012), restoring Neuronal nitric Oxide syn-
thase (nNOS) expression (Ii et al., 2005) and antioxidant 
effect (Santos Fdo, Watanabe, Vasco, Fonseca, & Vatti-
mo Mde, 2014); these effects might play important roles 
in pain improvement in neuropathic pain models. Proin-
flammatory cytokines such as IL-6, have been reported 
with their upregulating effect following nerve injury 
(Lee, Lee, Son, Hwang, & Cho, 2004). Inflammation 
activation is the main cause of chronic disease (Darabi, 
Hasanvand, & Nourollahi, 2016). 
In our study, we found that neuropathic pain leads to 
increase in the level of inflammatory markers, including 
TNF-α and IL-6. It has already been demonstrated that 
TNF-α plays an important role in central and periph-
eral pains and enhances sensitivity to different stimuli 
(Leung & Cahill, 2010). However, treatment with ro-
suvastatin resulted in reducing TNF-α levels subjected 
to chronic constriction injury-induced by CCI. Several 
studies have shown that anti-inflammatory potential of 
rosuvastatin through leukocyte adhesion inhibition re-
duces the production of inflammatory mediators and its 
antioxidant effect. In another study conducted in 2006, 
rosuvastatin was shown to reduce intestinal ischemic-
reperfusion injury. Rosuvastatin was also associated 
with increase in serum nNOS level and to improve vas-
cular structure (Naito et al., 2006).
Based on several studies, IL-6 may contribute to me-
chanical allodynia induced by spinal nerve lesion and 
CCI (Ramer, Murphy, Richardson, & Bisby, 1998; Mur-
phy et al., 1999). Also, it has been found that SHR-CRP 
transgenic mice treated with rosuvastatin reduces the 
levels of the inflammatory factors, e.g. TNF-α and IL-6, 
and subsequently reduces the inflammation and oxida-
tive damages (Silhavy et al., 2014). On the other hand, 
rosuvastatin reduces glial cells and lowers IL-1 levels 
and thus reduces the damages caused by neuropathic 
pain (Shi, Lim, Lee, Zhao, & Zhang, 2011). 
Rosuvastatin plays a significant role in improving per-
sistent pain and pain behaviors (Siniscalco et al., 2007). 
Preclinical studies have supported that the oxidative stress 
could enhance neuropathic pain and hyperalgesia which 
are strongly induced by peripheral nerve and or spinal 
cord injury in animal models of persistent pain (Kim, 
Wang, Lu, Chung, & Chung, 2009). Rosuvastatin use 
has a protective effect on oxidative stress by inducing Su-
peroxide Dismutase 1 (SOD1) expression (Verreth et al., 
2007). Enhancing the expression of glutathione synthase, 
GPx, glutathione reductase, and glutamylcysteine synthe-
tase has been also related to rosuvastatin use (Mahalwar & 
Khanna, 2013). In a previous study, it has been shown that 
rosuvastatin possesses antioxidant, anti-inflammatory, and 
analgesic activities in a dose-dependent manner (Ghaisas, 
Dandawate, Zawar, Ahire, & Gandhi, 2010).
Rosuvastatin has beneficial effects in neuroprotective 
activity against spinal cord ischemia/reperfusion injury 
(Die, Wang, Fan, Jiang, & Shi, 2010), ischemic brain 
injury (Savoia, Sisalli, Di Renzo, Annunziato, & Scorzi-
ello, 2011), traumatic brain injury (Sanchez-Aguilar et al., 
2013), and l-glutamate-induced excitotoxicity (Domoki et 
al., 2010). Finally, it has been shown that rosuvastatin has 
protective effects on nerve (Savoia et al., 2011; Yavuz et 
al., 2013).
In summary, rosuvastatin was effective in reducing neu-
ropathic pains. Rosuvastatin use decreases inflammatory 
markers and oxidative stress. Our findings support the an-
ti-inflammatory and antioxidant effects of rosuvastatin in 
the CCI-induced neuropathic pain in animal model. Also, 
our study suggests that rosuvastatin may have a neuropro-
tective effect in chronic constriction injury.
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